Investors Reward Forecast Upgrade with Stock Surge to a 52-Week High!
The revenue in Q1 increased by approximately 57% compared to the same period last year. The forecast upgrade indicates further growth throughout the year!
If profitability is achieved earlier, the upward trend could ascend to further 52-week highs!
Reading Time: 1 minute
BioCryst Pharmaceuticals Inc. (BCRX) (i.) crushed analysts' expectations with the numbers released for Q1 on May 5th. The driving force was a high demand for ORLADEYO containing the active ingredient Berotralstat, which is used for the prevention of swelling attacks in people with hereditary angioedema (HAE). HAE causes recurrent painful and sometimes life-threatening swellings, for example, in the face, neck, abdomen, or limbs. As demand is expected to continue to rise, the company has also raised its annual forecast. The company now expects to...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
